Clinical Trial Update: Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating BAY 59-7939 (rivaroxaban) for prevention of venous thromboembolism in patients undergoing elective total hip replacement…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• BAY 59-7939 (rivaroxaban) (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED